Lantheus Holdings, Inc. (LNTH)
In Vitro & In Vivo Diagnostic Substances · Healthcare · $6.8B
Intrinsic Value (Consensus)
$50.44
Current Price
$105.03
Margin of Safety
-52%
52% Above Intrinsic Value
Value: $50
Price: $105
Valuation Model Estimates
Current Price: $105.03
DCF (Discounted Cash Flow)
$64.61
Graham Number
$35.85
Earnings Power Value
$33.11
Relative Value (P/E)
$68.20
Dividend Discount Model
Not applicable
—
Consensus Value
$50.44
Model Assumptions
Discount Rate
10.3%
Growth Rate
2.0%
Terminal Growth
2.5%
Risk-Free Rate
4.3%
Discount rate derived from CAPM (risk-free rate + beta × market risk premium). Growth rate based on trailing earnings growth, capped at 20%.
Health Score
C
58
Profitability
22/25
Strength
22/25
Valuation
7/25
Growth
7/25
Financial Health Signals
Strong profitability — ROE of 21% (above 20% is excellent)
Key Financials
- EPS (TTM)
- $3.41
- EPS (Forward)
- $3.48
- Book Value
- $16.75
- P/E Ratio
- 20.0
- Forward P/E
- 19.6
- PEG Ratio
- —
- ROE
- 21.4%
- Debt/Equity
- 51%
- Revenue Growth
- 0.5%
- Earnings Growth
- 2.0%
- Dividend Yield
- N/A
- Beta
- 1.00
Similar Stocks (Healthcare)
ABEOAbeona Therapeutics ...
$37.06+300%
ABUSArbutus Biopharma Co...
$18.93+300%
ADVBAdvanced Biomed Inc....
$26.66+300%
AGENAgenus Inc.
$20.19+300%
ATRAAtara Biotherapeutic...
$41.43+300%
Data last updated: 2026-06-16
Source: Yahoo Finance